We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

He also worked on The Journal’s publishing desk; as a writer and editor covering stocks at Barron’s; as an editor of features at MarketWatch; and on product development efforts at The Journal.  ...

Concerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

COVID-19 showed the flaws in our approach to vaccine communication. Two public health experts suggest ways to fix them.

Bullish option flow detected in Moderna (MRNA) with 76,253 calls trading, 1.4x expected, and implied vol increasing almost 8 points to 77.82%. Feb-25 35 calls and Feb-25 34 calls are the most active ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

The first vaccines are due to be produced at the new facility in 2025. It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running a number of ...

MDV: Multidose vial; NA: Not available ... influenza vaccination campaign estimated that the total time to get a vaccine ready to be administered per patient was 87 s for MDVs and 49.71 s for ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...